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Factors Affecting Growth Kinetics and
Spontaneous Metastasis in the B16F10 Syngeneic
Murine Melanoma Model
Natalie Fowlkes, Kelli Clemons, Paul JF Rider, Ramesh Subramanian, Nobuko Wakamatsu, Ingeborg Langohr,
and Konstantin G Kousoulas*
Melanoma is an immunogenic tumor that can metastasize quickly to proximal and distal sites, thus complicating the application of therapeutic modalities. Numerous mouse model systems have been used to gain understanding of the immunobiology and metastatic potential of melanoma. Here, we report the optimization of a syngeneic mouse melanoma model
protocol using the mouse B16-derived melanoma cell line B16F10 that ensures the production of tumors on mice pinnae that
are similar in size between animals and that enlarge in a time-dependent manner. In this model, B16F10 cells are first allowed
to develop tumors after injection in the interscapular area or flank of C57BL/6J mice. Subsequently, the tumors are harvested,
cells dissociated and injected into mouse pinnae. Dose-dependent studies revealed that injection of 2 × 105 cells allowed for
slow tumor enlargement, producing tumors averaging 100 mm3 within 2 to 3 wk with a metastatic frequency of 100%. This
experimental protocol will be useful in dissecting the immunobiology of melanoma tumor development and metastasis and
the evaluation of immunotherapeutic antimelanoma therapies.
DOI: 10.30802/AALAS-CM-18-000036

Melanoma is the sixth most common type of cancer overall
in humans, and its incidence has been increasing yearly in the
United States for the last 30 y. When cutaneous melanoma is
diagnosed at an early stage, patients can be cured through surgical excision of the tumor and can expect 5-y survival rates
as high as 97%. However, at least 13% of melanoma patients
already have metastasis to regional or distant sites by the time
they are diagnosed with the disease. The most common first site
of melanoma metastasis is the sentinel lymph node (that is, the
first lymph node to which cancer cells are most likely to spread
from a primary tumor), and numerous studies have shown that
status of this lymph node reflects that of the entire topography
of regional lymph nodes.7,8,14,20
Metastasis is a significant problem in the treatment of cancer, accounting for more than 90% of cancer-related deaths in
people.9 Treatment options for while metastatic melanoma in
human patients particularly have been limited because metastatic melanoma is resistant to most traditional cancer therapies.
Efforts to improve the efficacy of novel treatment strategies and
minimize the incidence of adverse events are ongoing in clinical
trials. In many cases, these trials are occurring in advance of the
preclinical studies that are intended to support them.18 In other
cases, preclinical studies were performed and showed promising results in the laboratory, but therapeutic benefit failed to
translate to human clinical trials. The lack of appropriate models
for thorough preclinical testing of treatment strategies is often
blamed for these failures.3
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The metastatic behavior of melanoma is a specific challenge
in murine tumor modeling. Typically, an experimental metastasis model involves direct injection of neoplastic cells into the
bloodstream, most commonly into the tail vein of mice. Pulmonary nodules resulting from intravenous injection are frequently
referred to as metastases; however, intravenous injection leads
to the production of a multitude of de novo tumors, because
key steps in the metastatic cascade, including invasion into the
tissue, detachment, and migration into the vasculature (intravasation), are bypassed completely.21 In contrast, spontaneously
metastasizing models allow the entire metastatic cascade to be
modeled from invasion to colonization of distant sites.13 In addition, spontaneously metastasizing models allow meaningful
comparison of differences in protein or gene expression or immune cell infiltration between primary and metastatic lesions.
The B16 cell line is the most widely used line for melanoma
research due to its aggressive growth, and it remains the standard in the field for the development of immunotherapies for
melanoma.21,28 Nonetheless, the B16 melanoma line does not
typically form spontaneous metastases after subcutaneous implantation.17 To simulate pulmonary metastasis with this model,
B16F10 cells are typically injected into the tail vein in an acute
experimental metastasis model, as mentioned previously.21 Loss
of the metastatic phenotype may in part be related to years of
maintenance in vitro.6 In addition, changes in the inoculation
site can often alter tumor growth characteristics.19,25,26 Protocols
that establish consistent growth and predictable, spontaneous
metastasis in robust murine tumor models are therefore greatly
needed in cancer drug development for early preclinical studies. Here, we describe a C57BL/6J/B16F10 mouse melanoma
protocol that allows for the development of B16F10 tumors on
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Figure 1. (A) Schematic demonstrating a typical engraftment protocol in the B16F10 murine melanoma model. (B) Subcutaneous B16F10 melanoma tumors in the interscapular region at 2 wk after engraftment. Engraftment of B16F10 cells in this location results in variable tumor morphology and growth in C57BL/6J mice.

mouse pinna that are similar in size between animals after initial
engraftment in mouse interscapular or flank areas. This model
allows for the development of sizeable tumors within 2 to 3 wk
and efficient metastasis to regional lymph nodes.

Materials and Methods

Animals. Female C57BL/6J female mice (age, 6 to 8 wk) were
purchased from the Jackson Laboratory (Bar Harbor, ME). Animals were acclimated for at least 3 d prior to experimental use.
Mice were identified by using ear tags in the right pinna. Animals were housed under standard conditions with no more
than 5 per cage. Mice were housed in ventilated, filter-top cages
containing corncob bedding (catalog 7097, 1/4-in., Teklad, Envigo, Somerset, NJ) and were maintained on a 12:12-h light:dark
cycle at 22 ± 2 °C. Enrichment was provided in the form of social
housing and cotton nesting material. Mice had free access to
chow (no. 5001, LabDiet, St Louis, MO) and tap water. Animals
were maintained in accordance with the Guide for the Care and
Use of Laboratory Animals12 in an AAALAC-accredited facility.
All procedures were approved by the Louisiana State University IACUC and followed applicable governmental policies and
regulations.
Cell culture propagation. B16F10 murine melanoma cells were
obtained from American Type Culture Collection (Vienna, VA),
maintained under sterile conditions at 37 °C with 5% CO2, and
propagated as adherent monolayers in T75 flasks containing
DMEM supplemented with 10% filtered, heat inactivated FBS
and 100 µg/mL Primocin (Invivogen, San Diego, CA). Prior to

use, cells were trypsinized, centrifuged, counted by using a hemocytometer, and resuspended to the desired concentration in
sterile PBS. Trypan blue exclusion was performed to evaluate
cell viability during counting; cell viability was at least 90% for
all experiments.
In vivo propagation. After shaving of the skin and disinfection
by using a 70% isopropyl alcohol-soaked gauze, 3 C57BL/6J
female mice were injected with 2 × 106 early-passage B16F10
cells suspended in 100 µL PBS in the interscapular subcutis. A
1-mL syringe with a 27-gauge needle was used for injections.
Subcutaneous engraftment occurred while animals were anesthetized with 2% to 3% isoflurane. At 10 to 14 d, mice were euthanized, and tumors (diameter, 1 to 1.5 cm) were processed for
pinna engraftment in additional mice. Tumors were isolated,
placed in a sterile culture dish, minced by using a scalpel blade,
and placed in an incubator at 37 °C with 5% CO2 with 3 mL of
trypsin for approximately 20 min. Cells were strained through a
40-µm strainer, and complete DMEM with 100 µg/mL Primocin
was added before counting on a hemocytometer and evaluating for viability by using trypan blue exclusion; cell viability
was 90% or greater for experiments. Cells were centrifuged and
resuspended in PBS at concentrations of 2 × 106 and 4 × 106 cells/
mL and placed on ice for transportation and pinna engraftment
within 1 h of harvesting.
Pinna engraftment. Mice were anesthetized with 2% to 3%
isoflurane, and B16F10 cells were engrafted orthotopically in
the dermis of the dorsal left dorsal pinna, which had been disinfected by using 70% isopropyl alcohol; a 1-mL syringe with a
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Table 1. Comparison of tumor growth and metastasis in B16F10-bearing mice according to the number of cells inoculated
No. of mice with No. of mice with
tumors/
metastasis/
No. of B16F10
total no.
total no. of mice
cells inoculated of mice (%)
with tumors (%)
2 × 105

10/11 (91%)

10/10 (100%)

4 × 10

17/17 (100%)

9/17 (53%)

5

Tumor volume
at detection
(mm3)

Tumor volume at
euthanasia (mm3)

6.1 ± 1.441

114.0 ± 48.7

481.7 ± 104.7

6.8 ± 0.8

130.3 ± 43.7

765.7 ± 135.3

Lag time (d)

Overall
survival (d)

Duration of
disease (d)

21 ± 0

27.1 ± 1.4a,b
15.8 ± 0.5

8.1 ± 0.7

c,d

Data are given as mean ± SEM, where appropriate.
a
P < 0.0001 (unpaired t test, parametric, 2-tailed)
b
P = 0.0026 (F test to compare variances)
c
P < 0.0001 (unpaired t test, parametric, 2-tailed)
d
P < 0.001(F test to compare variances)

Figure 2. C57BL/6J mice transplanted in the pinna with B16F10 cells from primary tumors. Tumor morphology at euthanasia at 3 wk (top) and
4 wk (bottom) after transplantation. Tumor morphology and growth is markedly uniform in the pinna engraftment protocol after in vivo tumor
cell propagation.

27-gauge needle was used for injections. Five female C57BL/6J
mice were engrafted with 4 × 105 early-passage B16F10 cells
propagated in cell culture as described. We engrafted 17 mice
each with 4 × 105 cells in 100 µL of sterile PBS and 12 mice each
with 2 × 105 cells in 100 µL of sterile PBS. Tumors were measured approximately every 7 to 10 d by using an electronic digital caliper (W80152, Performance Tool, Wilmar, Renton, WA),
and tumor volumes were calculated by using the formula
π/6 × length × width × height. Tumors were allowed to grow to
approximately 500 to 1000 mm3 or until they began to ulcerate.
Histology. After euthanasia, all mice underwent complete,
routine postmortem examination. Tumors were measured, and
evidence of metastasis was recorded. Tissues including tumor,
liver, lung, spleen, kidney, and mandibular lymph node were
collected, fixed in 10% neutral buffered formalin, processed routinely, paraffin-embedded, sectioned at 4 µm by using a microtome, and stained with hematoxylin and eosin.
Statistical analysis. Statistical analyses were performed by using Prism 7.03 (GraphPad Software, San Diego, CA). P values
less than 0.05 were considered significant. Differences in survival times were evaluated by generating Kaplan–Meier survival curves, and significance determined by using the log-rank

test. Sigmoidal and exponential growth models were fitted by
using nonlinear comparison of fits and Akaike information criteria; 95% confidence intervals of the fitted curves were graphed.
Unpaired t tests (parametric, 2-tailed) were used to compare the
high and low cell-density engraftment groups; F tests were used
to determine variance.

Results

In vivo characterization of in vitro-propagated B16F10 growth
and metastasis. Original experiments involved injecting B16
cells into the pinna or footpad.6 Currently, most cancer researchers engraft B16 cells in the subcutis in the interscapular area
or flank,17,21 as is done for many transplantable models. In our
experience with the B16F10 model, engraftment in this location
results in marked variability in growth and morphology (Figure 1);
in addition, spontaneous metastasis is not typical.
We aimed to characterize the in vivo growth kinetics of earlypassage B16F10 cells. We engrafted 5 mice with 4 × 105 B16F10
murine melanoma cells in the pinna after their propagation in
cell culture. Growth varied markedly between mice and was
generally saltatory. One of the 5 mice (20%) did not develop a
tumor over 4 wk; another animal had markedly delayed tumor
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Figure 3. Melanoma tumor metastasis in mice. (A) Tumor growth of high (circles) and low (squares) cell-density engraftment over time; symbols
colored red indicate that metastasis was detected. (B) Sentinel lymph node metastasis in a low cell-density–engrafted mouse. (C) Photomicrograph of sentinel lymph node metastasis (asterisk); Hematoxylin and eosin staining; magnification, 20×. (D). Focal area of lung metastasis in the
left lung lobe of a low cell-density–engrafted mouse. Magnification, 10×. (E) Photomicrograph of metastatic B16F10 cells in the lungs. Hematoxylin and eosin staining.

development and did not develop a visible tumor until week
4. Among the 4 animals that developed tumors, tumor size at 3
to 4 wk varied markedly, with the smallest and largest tumors

differing by almost 1000-fold. The marked variability in growth
kinetics prevented the ability to fit the data to either exponential
or sigmoidal mathematical growth models. Only one animal
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(25%) showed evidence of spontaneous metastasis (that is, to
the lungs) at postmortem examination; none of the animals had
metastasis to the sentinel lymph node. The marked variability in
growth rates and lag times would make tumor growth synchronization challenging for a high-throughput expanded study, and
the paucity of spontaneous metastases might be problematic for
researchers testing therapeutic efficacy in metastatic disease.
In vivo characterization of in vivo-propagated B16F10 growth
and metastasis. Tumor cells are influenced by strong selection
pressure in the tumor microenvironment.5 One published protocol the involved a period of in vivo growth in the subcutis
before engraftment in the pinna yielded spontaneous metastasis.2,22 Therefore, we engrafted B16F10 cells in the interscapular
subcutis, harvested the tumor, created a single-cell suspension,
and resuspended cells in PBS before engrafting 17 animals each
with 4 × 105 in vivo-propagated cells in the left pinna. All 17 animals (100%) developed a tumor (Table 1). Tumor growth generally was rapid, and a measurable tumor was present in 7 to 8
d for most animals. Mice required euthanasia between 13 and
18 d after engraftment, with the median survival time being
15 d. Evaluation of tumor volumes over time and interpolation of a standard curve showed that the growth pattern was
exponential; in a nonlinear comparison of goodness-of-fit test,
the probability (according to Akaike information criteria) that
the exponential model was correct was 89.91%, compared with
10.09% for the sigmoidal model. In addition, at necropsy, 9 of
the 17 mice had lymph node metastases (53%), and 2 of the 17
(12%) also developed lung metastasis, thus representing marked
improvement over engraftment directly from cell culture.
In light of a previous study10 that showed that the density of
the cell inoculum affected the frequency of spontaneous metastasis in a murine breast cancer model using 4T1 cells, we
tested whether inoculating fewer B16F10 cells increased metastasis. Therefore, we followed a similar preengraftment in vivo
propagation protocol as previously, except that we engrafted
mice each with approximately 2 × 105 cells (rather than 4 × 105
cells) in the left pinna. Of the 12 mice used in this experiment,
1 died unexpectedly shortly after engraftment and was therefore excluded from the analysis. Ten of the 11 remaining mice
developed tumors at the site of engraftment (91% engraftment
efficiency), and the tumor morphology was remarkably uniform
among most mice at 3 and 4 wk (Figure 2, Table 1). The time
to development of a clearly visible and measurable melanoma
tumor was 3 wk.
All 10 animals that were successfully engrafted with the
lower-density inoculum had gross or microscopic evidence of
spontaneous metastasis to either lymph node or lung, but metastasis was primarily limited to the ipsilateral sentinel lymph
node (mandibular lymph node) for most animals (Figure 3).
Euthanasia was necessary between 21 and 32 d after engraftment, averaging 27 d. Of the 3 animals necropsied at 21 d (3 wk),
2 (67%) animals had evidence of spontaneous metastasis to the
ipsilateral regional (mandibular) lymph node at necropsy. The
third mouse had micrometastasis to the lungs (33%), but lymph
node metastasis was not identified. At 28 to 32 d (4 to 4.5 wk),
all 7 (100%) of the animals necropsied had metastasis to the ipsilateral mandibular lymph node, and 1 of these (14%) also had
micrometastasis to the lungs.
Plotting of survival times in Kaplan–Meier curves showed
that mice engrafted with a lower cell density survived longer
(log-rank P < 0.0001; Figure 4) than those inoculated with more
cells. Although mice experienced an exponential growth phase,
when interpolated to a standard curve, the growth pattern using
the lower cell density was a better fit for a sigmoidal model, in

Figure 4. Kaplan–Meier survival curves comparing overall survival
of mice engrafted with melanoma B16F10 cells. Overall survival times
are increased in mice inoculated with lower cell doses, an effect of protracted lag times in tumor development. Log-rank P ≤ 0.0001.

contrast to findings for the high cell-density–engrafted group;
in a nonlinear comparison of goodness-of-fit test, the probability that the sigmoidal model was correct for the low-density
inoculum was 87.91% compared with 12.09% for the exponential model (Figure 5, Table 2). These findings suggest that the
improved metastatic efficiency may be related to increased survival times. The increase in survival time appears to be a function of increased lag time, but the duration of the disease once
tumors became apparent did not vary significantly, regardless of
the cell density of the inoculum (Table 1).

Discussion

We report here the optimization of a syngeneic mouse model
system for melanoma that allows for relatively uniform growth
of tumors between engrafted animals and efficient metastasis
to regional lymph nodes. This model depends on the in vivo
growth of B16F10 cells in the subcutis of mice prior to pinna engraftment, which improves tumor growth synchronization and
enhances spontaneous metastasis of B16F10 murine melanoma.
In addition, an inoculum of 2 × 105 cells for pinna engraftment
increased lag times and enhanced metastatic efficiency.
It is generally accepted that the ideal tumor model system
would exhibit predictable gross morphology, growth, and metastatic behavior.23,27 In addition, prediction of the time of onset
and incidence or engraftment rate is critical for robust, preclinical testing of early tumor stages.18 Synchronization of tumor development is currently best achievable by using transplantable
models, and the protocol we described here resulted in reasonable engraftment efficiency and synchronization in growth after
in vivo propagation in the subcutis. High uniformity in morphology, growth, and spontaneous metastasis was achievable
with the B16F10 murine melanoma model we described here.
The observed uniform tumor morphology may at least partially
reflect the engraftment site chosen. Tumor cells are less mobile
when injected into the small potential space of the pinna dermis
as compared with the loose interscapular subcutis, thus perhaps
resulting in more consistent tumor morphology.
The pinna has been reported as a permissible site for engraftment of a wide variety of tissue types,4 and engraftment
in this location as compared with the subcutaneous tissue may
be one factor in supporting tumor growth and potentiating
spontaneous metastasis. The mouse pinna has a rich vascular
bed. Recruitment of tumor-associated vasculature is important for tumor engraftment success and growth. In addition,
the rich lymphatic supply in this region allows for easy access
of neoplastic cells to lymphatic vessels, which could enhance
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Figure 5. Fitting of in vivo growth of high and low cell-density engraftment of B16F10 cells to mathematical cell-growth models. (A) Composite
of the tumor growth curves. Sigmoidal and exponential growth models were fitted by using nonlinear comparison of fits and AIC for mice
engrafted with (B) 4 × 105 cells or (C) 2 × 105 cells. The red line represents the interpolated line generated by the data. The blue or black line represents the best-fit curve. Dotted lines designate the 95% confidence interval of the fitted curve. Solid points represent the mean tumor volume
(bars, SEM). Specific growth rates (SGR) were calculated by using the formula ln(volume 2 / volume 1) / time 2 – time 1, and doubling times
were calculated by using the formula ln2 / SGR.
Table 2. Fitting parameters of in vivo growth of B16F10 cells at different cell densities
No. of B16F10 cells
inoculated

Best-fit
growth model

Akaike information criteria
probability

Doubling time (d)

Specific growth rate
(% Δ/d)

4 × 105

Exponential

89.9%

1.7 ± 0.1

0.43 ± 0.10

2 × 105

Sigmoidal

87.9%

2.5 ± 0.4

0.40 ± 0.01

metastatic capabilities to sentinel lymph nodes (the ‘anatomical–mechanical’ metastasis hypothesis).16 Spontaneous metastasis after pinna engraftment has been reported in a variety of
tumor modeling protocols, including Lewis lung carcinoma and
melanoma.1,2,11,22 In addition, from a practical standpoint, monitoring of tumor growth is easier in the poorly haired area of
the mouse pinna than in the heavily haired areas on the trunk.
Engraftment in the poorly haired area of the pinna obviates the
need for extensive or frequent shaving necessary for monitoring tumor growth in the interscapular area or flank. All of these
features make the mouse pinna a favorable site for successful
tumor engraftment and sustained growth and spread of tumor
cells in the B16F10 murine melanoma model.
In addition, in the ideal tumor model system, tumor behavior,
including metastasis, should simulate natural progression of
the disease as is seen in humans. Intradermal orthotopic injection in the pinna more accurately mimics natural progression
than injection directly into subcutaneous fat. The period of in
vivo growth prior to transplantation to the dermis of experimental subjects may enhance local invasiveness of the tumor
cells from the dermis to the subcutis and ultimately spread to
lymph nodes, because tumor microenvironment can influence
metastatic behavior (the ‘seed and soil’ metastasis hypothesis).5
We observed that decreasing the density of the cell inoculum
at engraftment increases the lag time to tumor development
and overall survival times, allowing sufficient time for highly
predictable, spontaneous sentinel lymph node metastasis to occur. In most mice, metastasis to the sentinel lymph node was
obvious at postmortem examination. Metastasis to the sentinel
lymph nodes, which is the most common first site of metastasis
in humans and predictive of the entire topography of regional
lymph nodes, accurately and predictably models tumor behavior in melanoma patients with stage III disease.29
Interestingly, a 2-fold lower cell density produced significantly higher levels of spontaneous metastasis in our mice, in
agreement with the findings of authors who described the effects of inoculated cell density as a factor in growth dynamics
and metastatic efficiency in a syngeneic breast cancer murine
model.10 Perhaps the general principle of decreasing cell density

to enhance predictable growth and spontaneous metastasis is
applicable to a wide range of transplantable syngeneic models.
Overall, tumor growth was much more predictable and uniform after cells were grown in the subcutis of a mouse before engraftment into the pinnae of other mice, and growth data could
be interpolated to a standard curve, unlike for mice engrafted
with in vitro propagated tumor cells. Under natural conditions,
tumor growth in human patients is often observed to be saltatory,15,24 but asynchronization can cause considerable challenges
in tumor modeling and in interpreting the response to treatment
in efficacy studies involving mice. There are 2 commonly argued explanations for variations in growth observed in patients
over time, with neither hypothesis necessarily being mutually
exclusive. One is that waves of angiogenesis and tumor infarction and necrosis cause alternating periods of adequate delivery
of oxygen and nutrients, followed by periods of oxygen and
nutrient deprivation resulting in undulating variation in tumor
growth capacity over time.15 The other hypothesis is that selection pressure results in the generation of mutated cells with
inherently improved ability to adapt to the microenvironment
and enhanced proliferative capacity; these mutant cancer cells
can arise at various times resulting in marked variation in tumor
growth and growth rates, even under experimental conditions.15
Our findings are highly supportive of this ‘selection pressure’
hypothesis in particular. A period of preengraftment in vivo
selection may help to ‘preselect’ for cells that are most able to
adapt to the harsh conditions of the tumor microenvironment
and result in more predictable growth in experimental subjects.
Reproducibility is a major challenge in preclinical oncology
studies using preclinical murine tumor models. Understanding
the growth kinetics and metastatic capabilities of the specific
model through its optimization prior to experimentation can
aid in enhancing reproducibility and improved use of existing models will contribute to improved concordance of animal
studies and human patient outcomes at clinical trial. Detailed
analysis and characterization of factors that affect growth kinetics and metastatic phenotype in the B16F10 murine melanoma model will aid in most efficient use of this model system.
The principles we discuss here may also be relevant for other
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transplantable tumor models and may have wide applicability
in tumor modeling in general.
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